Medicinova Inc (MNOV) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Medicinova Inc (NASDAQ: MNOV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.40 (0.00% 1D, market cap $68.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MNOV ranks #854 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNOV carries a Roarable E (30/100 RQD), trailing P/E of 5.7x, gross margin of —, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $69.6M) and ZYBT (Zhengye Biotechnology Holding Limited (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).
Per MNOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001226616), Medicinova Inc generated $409.7K in revenue, $12.0M in net income, and -$9.8M in free cash flow against $45.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 7% of 52W Range • RSI-14 at 38.4 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±10.5% realized swing band)
Capital intensity & 0% operating margin leave 16 pts on the table
While MNOV currently carries a cautious 30/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.79) and Max Pain ($1.47) forces dealer call-delta covering toward $4.09.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Medicinova Inc (MNOV) slipped 0.00% to $1.40, trading at 7% of its 52-week range ($1.22 – $3.9). Stretched risk/reward at 6x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.
LA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)
To Fellow Shareholders,We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis (ALS). Recently, we announced topline results of our Phase 2
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)
MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fat
MediciNova Inc (NASDAQ:MNOV) shares fell 14. 7% in premarket trading on Monday after the company reported topline results from a Phase 2 clinical trial evaluating tipelukast, or MN-001, in patients with nonalcoholic fatt
Investing.com -- MediciNova Inc (NASDAQ:MNOV) shares fell 14.7% in premarket trading Monday following mixed results from a Phase 2 clinical trial evaluating tipelukast (MN-001) for the treatment of nonalcoholic fatty liv
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fatLA JOLLA, Calif., Sept. 28, 2026 (G
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)
LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875),
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MNOV today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MNOV. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Medicinova Inc (MNOV) ranks #854 by composite RQD confidence (30/100, grade E) and #709 by equity capitalization ($68.9M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with MNOV at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MNOV
ACTIVE
Medicinova Inc | E | 30/100 | 5.7x | — | -35.0% | 0.00% | $68.9M | Benchmark Subject |
| TENX Tenax Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | -3.76% | $69.6M | /tenx-vs-mnov → |
| ZYBT Zhengye Biotechnology Holding Limited (Class A) | D- | 40/100 | — | 20.5% | -22.3% | -9.09% | $67.8M | /zybt-vs-mnov → |
| OSTX OS Therapies Incorporated | D- | 42/100 | — | — | -35.0% | -4.61% | $67.6M | /ostx-vs-mnov → |
| RNXT RenovoRx Inc. | E | 31/100 | — | 70.9% | -35.0% | -10.74% | $67.2M | /rnxt-vs-mnov → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Medicinova Inc (MNOV) reported GAAP revenue of $409.7K (N/A vs. FY2024 revenue of $0 , and -59.0% cumulative change since FY2023) , GAAP net income of $12.0M, operating cash flow of -$9.8M, and free cash flow of -$9.8M (+7.8% YoY). On the balance sheet, MNOV closed FY2025 with $45.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $409.7K | $12.0M | -$9.8M | -$9.8M | $45.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | $11.1M | -$10.6M | -$10.6M | $55.9M | — |
| FY2023 (FY) | 2023-12-31 | $1.0M | $8.6M | -$7.4M | -$7.4M | — | — |
As of 2026-11-02, Medicinova Inc (NASDAQ: MNOV) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.40 (0.00% 1D, market cap $68.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, MNOV ranks #854 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNOV carries a Roarable E (30/100 RQD), trailing P/E of 5.7x, gross margin of —, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $69.6M) and ZYBT (Zhengye Biotechnology Holding Limited (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).
Per MNOV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001226616), Medicinova Inc generated $409.7K in revenue, $12.0M in net income, and -$9.8M in free cash flow against $45.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MNOV last traded at $1.40 (0.00% on volume of 29,687 shares), positioning the stock -21.79% below its 50-day simple moving average ($1.79) and -7.28% below its 200-day simple moving average ($1.51). Across its 52-week range of $1.22 to $3.90, MNOV sits at the 6.7% percentile with a 14-day RSI of 38.4 (NEUTRAL RANGE) and an implied next-earnings move of ±10.5% ($1.25 to $1.55).
Why MNOV Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at 6x P/E (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD 5-pillar rating engine, Medicinova Inc (MNOV) carries a composite score of 30/100 (E — Roarable Strong Sell — Forensic Risk / Avoid) at a current price of $1.40 (0.00%). Fundamental cash generation scores 1/20 (ROIC -35.0%, FCF yield -14.24%), institutional 13F whale accumulation scores 7/20, insider conviction scores 5/20, macro regime alignment scores 10/20 (Beta 1.00), and forensic balance-sheet protection scores 7/20 (Altman Z-Score 0.20, Piotroski F-Score 3/9).
Investor Implication: At 5.7x trailing P/E and 5.3x forward P/E within Biotechnology: Pharmaceutical Preparations, upside depends on sustained operating margin expansion (-60.0%) and free cash flow conversion relative to the 52-week range of $1.22 – $3.90.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MNOV is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).
Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.
Real-time company headlines, analyst actions, and sector developments for Medicinova Inc (MNOV) • Click "Debate This Headline" to argue it in the Roar Pit below
LA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)
To Fellow Shareholders,We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis (ALS). Recently, we announced topline results of our Phase 2
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)
MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fat
MediciNova Inc (NASDAQ:MNOV) shares fell 14. 7% in premarket trading on Monday after the company reported topline results from a Phase 2 clinical trial evaluating tipelukast, or MN-001, in patients with nonalcoholic fatt
Investing.com -- MediciNova Inc (NASDAQ:MNOV) shares fell 14.7% in premarket trading Monday following mixed results from a Phase 2 clinical trial evaluating tipelukast (MN-001) for the treatment of nonalcoholic fatty liv
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fatLA JOLLA, Calif., Sept. 28, 2026 (G
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875)
Welcome to the MNOV (Medicinova Inc) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on MNOV, but look at what you are paying: 5.7x trailing P/E with tightening sector spreads. Unless Medicinova Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on MNOV, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.40 (52-wk range $1.22 - $3.90), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).